Beta Bionics Cash Flow Statement
NASDAQ: BBNXHealth CareMedical/Dental InstrumentsUSD
17.63+0.20 (+1.15%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Beta Bionics free cash flow
In fiscal 2025, Beta Bionics generated -$50.9 million of operating cash flow and spent $5.3 million on capital expenditures. That left free cash flow of -$56.2 million, a free-cash-flow margin of -56.1% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Beta Bionics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Net Income | -73.20M | -54.76M | -44.10M |
| Net Income growth (YoY) | — | — | — |
| Depreciation & Amortization | 1.57M | 1.15M | 1.23M |
| Stock-Based Compensation | 16.38M | 6.38M | 5.66M |
| Change in Working Capital | -16.70M | -17.93M | -5.01M |
| Operating Cash Flow | -50.92M | -48.27M | -32.45M |
| Capital Expenditures | -5.30M | -3.40M | -402.00K |
| Investing Cash Flow | -162.81M | -3.48M | -69.69M |
| Financing Cash Flow | 214.87M | 55.62M | 101.03M |
| Net Change in Cash | 1.14M | 3.87M | -1.11M |
| Free Cash Flow | -56.22M | -51.67M | -32.85M |
This table shows 3 annual periods of Beta Bionics's cash flow statement, from FY 2025 back to FY 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BBNX's reporting calendar. What is a cash flow statement?